Three month treatment of acute VTE with Fragmin in pediatric cancer patients
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT00952380.
Primary study objectives include are to determine the pharmacodynamic (PD) profiles for
treatment doses of dalteparin in pediatric subjects of different ages with cancer and
venous thromboembolism (VTE), using anti-Xa (Xa) levels and a population PD analysis
methodology, and to determine the median dose required to achieve therapeutic anti- Xa
levels (0.5 to 1.0 International Units [IU]/mL) based on subject age and weight.
Lead OrganizationPfizer Inc
